** Shares of drugmaker Eli Lilly LLY.N fall 4.3% to $860.72 premarket
** Q1 sales of its popular weight-loss drug, Zepbound, came in slightly below Wall Street estimates
** Zepbound posted Q1 sales of $2.31 billion compared with analysts' average estimate of $2.33 billion, as per data compiled by LSEG
** Co also cuts annual adj. profit forecast to between $20.78 and $22.28 per share from $22.50 and $24 previously
** Sales of diabetes drug Mounjaro came in at $3.84 billion, compared with estimates of $3.80 billion- LSEG
** Up to last close, LLY was up 16.4% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。